A condition characterized by a chronically swollen limb, often a leg with stasis dermatitis and ulcerations. This syndrome can appear soon after phlebitis or years later. Postphlebitic syndrome is the result of damaged or incompetent venous valves in the limbs. Distended, tortuous VARICOSE VEINS are usually present. Leg pain may occur after long period of standing.
Material used for wrapping or binding any part of the body.
Inflammation of a vein associated with a blood clot (THROMBUS).
A characteristic symptom complex.
A term used to describe a variety of localized asymmetrical SKIN thickening that is similar to those of SYSTEMIC SCLERODERMA but without the disease features in the multiple internal organs and BLOOD VESSELS. Lesions may be characterized as patches or plaques (morphea), bands (linear), or nodules.
A synthetic steroid that has anabolic and androgenic properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1194)
A condition in which the death of adipose tissue results in neutral fats being split into fatty acids and glycerol.
Skin breakdown or ulceration caused by VARICOSE VEINS in which there is too much hydrostatic pressure in the superficial venous system of the leg. Venous hypertension leads to increased pressure in the capillary bed, transudation of fluid and proteins into the interstitial space, altering blood flow and supply of nutrients to the skin and subcutaneous tissues, and eventual ulceration.
A nonspecific term used to denote any cutaneous lesion or group of lesions, or eruptions of any type on the leg. (From Stedman, 25th ed)
Impaired venous blood flow or venous return (venous stasis), usually caused by inadequate venous valves. Venous insufficiency often occurs in the legs, and is associated with EDEMA and sometimes with VENOUS STASIS ULCERS at the ankle.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)

Relief of obstructive pelvic venous symptoms with endoluminal stenting. (1/36)

PURPOSE: To select patients for percutaneous transluminal stenting of chronic postthrombotic pelvic venous obstructions (CPPVO), we evaluated the clinical symptoms in a cohort of candidates and in a series of successfully treated patients. METHODS: The symptoms of 42 patients (39 women) with CPPVO (38 left iliac; average history, 18 years) were recorded, and the venous anatomy was studied by means of duplex scanning, subtraction venography, and computed tomography or magnetic resonance imaging. Successfully stented patients were controlled by means of duplex scanning and assessment of symptoms. RESULTS: The typical symptoms of CPPVO were reported spontaneously by 24% of patients and uncovered by means of a targeted interview in an additional 47%. Of 42 patients, 15 had venous claudication, four had neurogenic claudication (caused by dilated veins in the spinal canal that arise from the collateral circulation), and 11 had both symptoms. Twelve patients had no specific symptoms. Placement of a stent was found to be technically feasible in 25 patients (60%), was attempted in 14 patients, and was primarily successful in 12 patients. One stent occluded within the first week. All other stents were fully patent after a mean of 15 months (range, 1 to 43 months). Satisfaction was high in the patients who had the typical symptoms, but low in those who lacked them. CONCLUSION: Venous claudication and neurogenic claudication caused by venous collaterals in the spinal canal are typical clinical features of CPPVO. We recommend searching for these symptoms, because recanalization by means of stenting is often feasible and rewarding.  (+info)

Mid-term results of endoscopic perforator vein interruption for chronic venous insufficiency: lessons learned from the North American subfascial endoscopic perforator surgery registry. The North American Study Group. (2/36)

PURPOSE: The safety, feasibility, and early efficacy of subfascial endoscopic perforator surgery (SEPS) for the treatment of chronic venous insufficiency were established in a preliminary report. The long-term clinical outcome and the late complications after SEPS are as yet undetermined. METHODS: The North American Subfascial Endoscopic Perforator Surgery registry collected information on 148 SEPS procedures that were performed in 17 centers in the United States and Canada between August 1, 1993, and February 15, 1996. The data analysis in this study focused on mid-term outcome in 146 patients. RESULTS: One hundred forty-six patients (79 men and 67 women; mean age, 56 years; range, 27 to 87 years) underwent SEPS. One hundred and one patients (69%) had active ulcers (class 6), and 21 (14%) had healed ulcers (class 5). One hundred and three patients (71%) underwent concomitant venous procedures (stripping, 70; high ligation, 17; varicosity avulsion alone, 16). There were no deaths or pulmonary embolisms. One deep venous thrombosis occurred at 2 months. The follow-up periods averaged 24 months (range, 1 to 53 months). Cumulative ulcer healing at 1 year was 88% (median time to healing, 54 days). Concomitant ablation of superficial reflux and lack of deep venous obstruction predicted ulcer healing (P <.05). Clinical score improved from 8.93 to 3.98 at the last follow-up (P <. 0001). Cumulative ulcer recurrence at 1 year was 16% and at 2 years was 28% (standard error, < 10%). Post-thrombotic limbs had a higher 2-year cumulative recurrence rate (46%) than did those limbs with primary valvular incompetence (20%; P <.05). Twenty-eight of the 122 patients (23%) who had class 5 or class 6 ulcers before surgery had an active ulcer at the last follow-up examination. CONCLUSIONS: The interruption of perforators with ablation of superficial reflux is effective in decreasing the symptoms of chronic venous insufficiency and rapidly healing ulcers. Recurrence or new ulcer development, however, is still significant, particularly in post-thrombotic limbs. The reevaluation of the indications for SEPS is warranted because operations in patients without previous deep vein thrombosis are successful but operations in those patients with deep vein thrombosis are less successful. Operations on patients with deep vein occlusion have poor outcomes.  (+info)

Intermittent compression units for severe post-phlebitic syndrome: a randomized crossover study. (3/36)

BACKGROUND: Although uncommon, severe post-phlebitic syndrome may be associated with persistent, intractable pain and swelling that interfere with work and leisure activities. This study was performed to determine whether intermittent compression therapy with an extremity pump benefits patients with this condition and, if so, whether the benefit is sustained. METHODS: The study was a randomized crossover trial. Over the period 1990 to 1996, all patients in the clinical thromboembolism program of an Ontario teaching hospital who had a history of deep vein thrombosis and intractable symptoms of post-phlebitic syndrome were recruited into the study. The study involved using an extremity pump twice daily for a total of 2 months (20 minutes per session). The patients were randomly assigned to use either a therapeutic pressure (50 mm Hg) or a placebo pressure (15 mm Hg) for the first month. For the second month, the patients used the other pressure. A questionnaire assessing symptoms and functional status served as the primary outcome measure and was administered at the end of each 1-month period. A symptom score was derived by summing the scores for individual questions. At the end of the 2-month study, patients were asked to indicate their treatment preference and to rate the importance of the difference between the 12 pressures. Treatment was considered successful if the patient preferred the therapeutic pressure and stated that he or she would continue using the extremity pump and that the difference between the therapeutic and placebo pressures was of at least slight importance. All other combinations of responses were considered to represent treatment failure. Patients whose treatment was classified as successful were offered the opportunity to keep the pump and to alter pressure, frequency and duration of pump use to optimize symptom management. In July 1996 the authors contacted all study participants whose treatment had been classified as successful to determine whether they were still using the pump and, if so, whether they were still deriving benefit. RESULTS: In total 15 consecutive patients (12 women and 3 men) were enrolled in the study. The symptom scores were significantly better with the therapeutic pressure (mean 16.5) than with the placebo pressure (mean 14.4) (paired t-test, p = 0.007). The treatment for 12 of the patients (80%, 95% confidence interval 52% to 96%) was considered successful. Of these, 9 patients continued to use the pump beyond the crossover study and to derive benefit. INTERPRETATION: The authors conclude that a trial of pump therapy is worthwhile for patients with severe post-phlebitic syndrome and that a sustained beneficial response can be expected in most such patients.  (+info)

The postthrombotic syndrome in relation to venous hemodynamics, as measured by means of duplex scanning and strain-gauge plethysmography. (4/36)

PURPOSE: Venous hemodynamics were evaluated in relation to the postthrombotic syndrome (PTS) 7 to 13 years after deep venous thrombosis (DVT). METHODS: The presence of flow, reflux, and compressibility of 1394 vein segments in 82 patients was assessed by means of duplex scanning. The venous outflow resistance was measured by means of strain-gauge plethysmography. The venous hemodynamics were related to the clinical severity of the PTS, characterized by the CEAP (clinical, etiologic, anatomic, pathophysiologic) classification. RESULTS: In patients with severe clinical symptoms of PTS, the prevalence of reflux was significantly higher. There was no relationship between the severity of the PTS and the noncompressibility or the combination of reflux and noncompressibility or an increased venous resistance. By means of multiple regression analysis with the variables of age, gender, reflux, and venous resistance, age and reflux were shown to be the main contributors to the severity of PTS. Significantly more patients (64%) with severe signs of PTS had a combination of deep and superficial reflux. In each of the traceable vein segments, the mean of the CEAP classification was calculated for the vein segments with and without reflux. In the proximal superficial femoral vein (P <.001), distal superficial femoral vein (P <.05), and popliteal vein (P <.05), a significantly higher mean CEAP classification was found in the veins with reflux, whereas in the distal, long, and short saphenous veins, no such relationship was found. CONCLUSION: Most patients with severe PTS had a combination of deep and superficial reflux. Reflux in the deep proximal veins contributes significantly to the PTS.  (+info)

Leukocyte rheology before and after chemotactic activation in some venous diseases. (5/36)

OBJECTIVE: to evaluate leukocyte rheology, polymorphonuclear leukocyte (PMN) membrane fluidity and cytosolic Ca2+ concentration in subjects with post-phlebitic leg syndrome (PPS) and acute deep-venous leg thrombosis (DVT). SUBJECTS: twenty-two subjects with leg PPS and 14 subjects with leg DVT. METHODS: we evaluated the leukocyte filtration (unfractionated, mononuclear cells (MN) and PMN), the PMN membrane fluidity and the PMN cytosolic Ca2+ concentration. Subsequently, we evaluated the same PMN variables after in vitro chemotactic activation with 4-phorbol 12-myristate 13-acetate (PMA) and N -formyl-methionyl-leucyl-phenylalanine (fMLP). RESULTS: at baseline we observed a significant difference in the filtration variables of unfractionated and MN cells and in PMN cytosolic Ca2+ concentration. After activation, in normal subjects and subjects with PPS and DVT, a significant variation in PMN filtration at 5 and 15 minutes was evident. In normal subjects, no variation was present in PMN membrane fluidity or cytosolic Ca2+ concentration after activation. In subjects with PPS and DVT, we found a decrease in PMN membrane fluidity and an increase in PMN cytosolic Ca2+ concentration. After PMN activation (at 5 and 15 min) Delta% of IRFR distinguished normal subjects from subjects with PPS and DVT, while no difference was found in Delta% of membrane fluidity or cytosolic Ca2+ concentration. CONCLUSIONS: there is a functional alteration of leukocytes in these patients whose mechanisms are not yet clear.  (+info)

Long-term outcomes after deep vein thrombosis: postphlebitic syndrome and quality of life. (6/36)

In this review, we critically assess the literature on the incidence of postphlebitic syndrome, risk factors for its occurrence, available therapeutic options, and its effects on quality of life. As well, we describe available tools to measure postphlebitic syndrome. Recent prospective studies indicate that postphlebitic syndrome, a chronic, potentially disabling condition characterized by leg swelling, pain, venous ectasia, and skin induration, is established by 1 year after deep vein thrombosis (DVT) in 17% to 50% of patients. The only prospectively identified risk factor for its occurrence is recurrent ipsilateral DVT. In the sole randomized study available, daily use of elastic compression stockings after proximal DVT reduced the incidence of postphlebitic syndrome by 50%. Treatment options for established postphlebitic syndrome are limited, but include compression stockings and intermittent compressive therapy with an extremity pump for severe cases. To date, quality of life after DVT has received little attention in the literature. The recent development of the VEINES-QOL questionnaire, a validated venous-disease-specific measure of quality of life, should encourage researchers to include quality of life as a routine outcome measure after DVT. There is no criterion standard for the diagnosis of postphlebitic syndrome, but a validated clinical scoring system does exist. More research on postphlebitic syndrome is needed to enable us to provide DVT patients with comprehensive, evidence-based information regarding their long-term prognosis, to help quantify the prevalence and health care burden of postphlebitic syndrome, and by identifying predictors of poor outcome, to develop new preventive strategies in patients at risk of developing this condition.  (+info)

Endovascular surgery in the treatment of chronic primary and post-thrombotic iliac vein obstruction. (7/36)

OBJECTIVES: To compare the results and complications of endovascular surgery in limbs with post-thrombotic and non-thrombotic disease and to detail some technical aspects of the procedure. DESIGN: A single centre, prospective study. MATERIALS AND METHODS: Between March 1997 and August 1999, 139 consecutive lower extremities with chronic iliac venous obstruction (61 limbs with primary disease [MTS] and 78 with post-thrombotic disease [PTS]) were treated by balloon dilation and stenting. History, clinical examination, procedure and follow-up data were recorded. RESULTS: Mortality was zero. Non-thrombotic complication rate was only 3%. Postoperative (8%, 6/78) and late occlusion (3%, 2/69) occurred only in post-thrombotic limbs. Primary, primary-assisted and secondary cumulative patency rates of the stented area at 2 years were 52%, 88% and 90%, respectively, in the PTS group as compared to 60%, 100% and 100% in the MTS group. Clinical improvement in pain and swelling was significant in both groups. Half of active venous ulcers healed after the procedure. CONCLUSIONS: Chronic iliac vein obstruction appears to be a symptomatic lesion that can be treated safely and effectively by endovascular surgery regardless of aetiology. Generous use of IVUS is suggested in both diagnosis and treatment since phlebography is unreliable. The clinical improvement was significant in both groups; however, more excessive neointimal hyperplasia and a higher early and late occlusion rate were observed in post-thrombotic disease. Stenting after balloon dilation is advised in all venoplasties; stents should be inserted well into the IVC when treating iliocaval junction stenosis. A wide-diameter (16 mm) stent is recommended. The stent should cover the entire lesion as outlined by the IVUS.  (+info)

Long term complications of inferior vena cava thrombosis. (8/36)

AIM: To evaluate the long term outcome after paediatric inferior vena cava (IVC) thrombosis. METHODS: A combined retrospective and prospective study on infants and children with IVC thrombosis treated at Aachen and Maastricht University Hospitals between 1980 and 1999. RESULTS: Forty patients were enrolled, including four with preceding cardiac catheterisation, 18 with central venous saphenous lines, and an additional eight with umbilical venous catheters. Six patients died within three months of diagnosis; one patient was lost to follow up. Twelve of the remaining 33 patients had suffered from limited IVC thrombosis; during follow up (for up to nine years) none showed persisting caval obstruction (successful thrombolysis, n = 2; spontaneous recanalisation, n = 10). The remaining 21 patients presented with extensive IVC thrombosis. During follow up (for up to 18 years) complete restitution was found in only four cases (one thrombolysis, two surgery, one spontaneous recanalisation). Persisting iliac and/or caval venous obstruction occurred in 17 patients, including six with thrombolysis. Varicose veins were found in 12, and post-thrombotic syndrome in seven of these cases. According to Kaplan-Meier analysis, 30% of patients with persisting venous disease will develop post-thrombotic syndrome within 10 years of the thrombotic event. CONCLUSIONS: Infants and children with extensive IVC thrombosis are at high risk for persisting venous disease and serious long term complications. Prospective trials are urgently needed to establish effective treatment strategies and to improve long term prognosis. Central venous catheters, contributing to IVC thrombosis in the majority of cases reported here, should be inserted only if essential.  (+info)

Postphlebitic syndrome, also known as postthrombotic syndrome or post-thrombotic limb, is a long-term complication that can occur after deep vein thrombosis (DVT). It's characterized by chronic venous insufficiency due to damage in the valves and walls of the affected veins. This results in impaired return of blood from the extremities back to the heart, leading to symptoms such as:

1. Swelling (edema) in the affected limb, usually the lower leg or calf.
2. Pain, aching, or cramping in the legs.
3. Heaviness or fatigue in the legs.
4. Skin changes like redness, warmth, or itchiness.
5. Development of venous ulcers or sores, particularly around the ankles.

The severity of postphlebitic syndrome can vary from mild to severe and may significantly impact a person's quality of life. Risk factors for developing this condition include having had a previous DVT, obesity, older age, lack of physical activity, and a family history of blood clotting disorders. Early diagnosis and appropriate management of deep vein thrombosis can help reduce the risk of developing postphlebitic syndrome.

A bandage is a medical dressing or covering applied to a wound, injury, or sore with the intention of promoting healing or preventing infection. Bandages can be made of a variety of materials such as gauze, cotton, elastic, or adhesive tape and come in different sizes and shapes to accommodate various body parts. They can also have additional features like fasteners, non-slip surfaces, or transparent windows for monitoring the condition of the wound.

Bandages serve several purposes, including:

1. Absorbing drainage or exudate from the wound
2. Protecting the wound from external contaminants and bacteria
3. Securing other medical devices such as catheters or splints in place
4. Reducing swelling or promoting immobilization of the affected area
5. Providing compression to control bleeding or prevent fluid accumulation
6. Relieving pain by reducing pressure on sensitive nerves or structures.

Proper application and care of bandages are essential for effective wound healing and prevention of complications such as infection or delayed recovery.

Thrombophlebitis is a medical condition characterized by the inflammation and clotting of blood in a vein, usually in the legs. The term thrombophlebitis comes from two words: "thrombo" which means blood clot, and "phlebitis" which refers to inflammation of the vein.

The condition can occur in superficial or deep veins. Superficial thrombophlebitis affects the veins just below the skin's surface, while deep vein thrombophlebitis (DVT) occurs in the deeper veins. DVT is a more serious condition as it can lead to complications such as pulmonary embolism if the blood clot breaks off and travels to the lungs.

Symptoms of thrombophlebitis may include redness, warmth, pain, swelling, or discomfort in the affected area. In some cases, there may be visible surface veins that are hard, tender, or ropy to touch. If left untreated, thrombophlebitis can lead to chronic venous insufficiency and other long-term complications. Treatment typically involves medications such as anticoagulants, antiplatelet agents, or thrombolytics, along with compression stockings and other supportive measures.

A syndrome, in medical terms, is a set of symptoms that collectively indicate or characterize a disease, disorder, or underlying pathological process. It's essentially a collection of signs and/or symptoms that frequently occur together and can suggest a particular cause or condition, even though the exact physiological mechanisms might not be fully understood.

For example, Down syndrome is characterized by specific physical features, cognitive delays, and other developmental issues resulting from an extra copy of chromosome 21. Similarly, metabolic syndromes like diabetes mellitus type 2 involve a group of risk factors such as obesity, high blood pressure, high blood sugar, and abnormal cholesterol or triglyceride levels that collectively increase the risk of heart disease, stroke, and diabetes.

It's important to note that a syndrome is not a specific diagnosis; rather, it's a pattern of symptoms that can help guide further diagnostic evaluation and management.

Localized scleroderma, also known as morphea, is a rare autoimmune disorder that affects the skin and connective tissues. It is characterized by thickening and hardening (sclerosis) of the skin in patches or bands, usually on the trunk, limbs, or face. Unlike systemic scleroderma, localized scleroderma does not affect internal organs, although it can cause significant disfigurement and disability in some cases.

There are two main types of localized scleroderma: plaque morphea and generalized morphea. Plaque morphea typically presents as oval or circular patches of thickened, hard skin that are often white or pale in the center and surrounded by a purple or darker border. Generalized morphea, on the other hand, is characterized by larger areas of sclerosis that can cover much of the body surface.

The exact cause of localized scleroderma is not fully understood, but it is thought to involve an overactive immune system response that leads to inflammation and scarring of the skin and underlying tissues. Treatment typically involves a combination of topical therapies (such as corticosteroids or calcineurin inhibitors), phototherapy, and systemic medications (such as methotrexate or mycophenolate mofetil) in more severe cases.

Stanozolol is a synthetic anabolic-androgenic steroid (AAS) derivative of dihydrotestosterone (DHT). It is commonly used in medicine for the treatment of hereditary angioedema and was formerly used to promote muscle growth in weakened or catabolic patients. Stanozolol has a high anabolic and moderate androgenic activity, with reduced estrogenic properties compared to testosterone. Its chemical formula is (17α-methyl-5α-androstano[2,3-c]pyrazol-17β-ol). It is important to note that the use of Stanozolol for performance enhancement is considered illegal and subject to severe penalties in many countries, including disqualification from sports events and criminal charges.

Fat necrosis is a medical condition that refers to the death (necrosis) of fat cells, typically due to injury or trauma. This can occur when there is an interruption of blood flow to the area, leading to the death of fat cells and the release of their contents. The affected area may become firm, nodular, or lumpy, and can sometimes be mistaken for a tumor.

Fat necrosis can also occur as a result of pancreatic enzymes leaking into surrounding tissues due to conditions such as pancreatitis. These enzymes can break down fat cells, leading to the formation of calcium soaps that can be seen on imaging studies.

While fat necrosis is not typically a serious condition, it can cause discomfort or pain in the affected area. In some cases, surgical intervention may be necessary to remove the affected tissue.

A varicose ulcer is a type of chronic wound that typically occurs on the lower leg, often as a result of poor circulation and venous insufficiency. These ulcers form when there is increased pressure in the veins, leading to damage and leakage of fluids into the surrounding tissues. Over time, this can cause the skin to break down and form an open sore or ulcer.

Varicose ulcers are often associated with varicose veins, which are swollen and twisted veins that are visible just beneath the surface of the skin. These veins have weakened walls and valves, which can lead to the pooling of blood and fluid in the lower legs. This increased pressure can cause damage to the surrounding tissues, leading to the formation of an ulcer.

Varicose ulcers are typically slow to heal and may require extensive treatment, including compression therapy, wound care, and sometimes surgery. Risk factors for developing varicose ulcers include obesity, smoking, sedentary lifestyle, and a history of deep vein thrombosis or other circulatory problems.

Leg dermatoses is a general term that refers to various skin conditions affecting the legs. This can include a wide range of inflammatory, infectious, or degenerative diseases that cause symptoms such as redness, itching, scaling, blistering, or pigmentation changes on the leg skin. Examples of specific leg dermatoses include stasis dermatitis, venous eczema, contact dermatitis, lichen planus, psoriasis, and cellulitis among others. Accurate diagnosis usually requires a thorough examination and sometimes a biopsy to determine the specific type of dermatosis and appropriate treatment.

Venous insufficiency is a medical condition that occurs when the veins, particularly in the legs, have difficulty returning blood back to the heart due to impaired valve function or obstruction in the vein. This results in blood pooling in the veins, leading to symptoms such as varicose veins, swelling, skin changes, and ulcers. Prolonged venous insufficiency can cause chronic pain and affect the quality of life if left untreated.

An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.

The meaning of POSTPHLEBITIC SYNDROME is chronic venous insufficiency with associated pathological manifestations (as pain, ... Post the Definition of postphlebitic syndrome to Facebook Facebook Share the Definition of postphlebitic syndrome on Twitter ... "Postphlebitic syndrome." Merriam-Webster.com Medical Dictionary, Merriam-Webster, https://www.merriam-webster.com/medical/ ...
Chronic Venous Insufficiency and Postphlebitic Syndrome - Etiology, pathophysiology, symptoms, signs, diagnosis & prognosis ... Postphlebitic syndrome is symptomatic chronic venous insufficiency that follows DVT. Risk factors for postphlebitic syndrome in ... Postphlebitic syndrome may affect 20 to 50% of patients with deep venous thrombosis Deep Venous Thrombosis (DVT) Deep venous ... Postphlebitic (postthrombotic) syndrome is symptomatic chronic venous insufficiency after deep venous thrombosis (DVT). Causes ...
DVT; Blood clot in the legs; Thromboembolism; Post-phlebitic syndrome; Post-thrombotic syndrome; Venous - DVT ...
Post-phlebitic syndrome. 7121 Post-surgical residual. 6844 Progressive muscular atrophy. 8023 Prostate gland injuries, ... Compartment syndrome. 5331 Complete or incomplete pelvic organ prolapse due to injury or disease or surgical complications of ...
In: . Stasis dermatitis and venous ulceration: Postphlebitic syndromes. New York, NY:Mosby, Inc.; 2004 PubMed. Transcutaneous ...
Popliteal Artery Entrapment Syndrome (Paes). *Portosystemic Shunt. *Postphlebitic Syndrome. *Pseudoaneurysm. *Radial Artery ...
Complications of DVT include postphlebitic syndrome or death from PE. Therefore, prophylaxis with anticoagulant medications, as ... Role of statins in the prevention of post-thrombotic syndrome after a deep vein thrombosis event: a systematic review and meta- ... suggested that statins may reduce postthrombotic syndrome after DVT; however, meta-analysis of the RCTs did not confirm any ...
Popliteal Artery Entrapment Syndrome * Postphlebitic Syndrome * Pseudoaneurysm * Recurrent Thrombosis * Renal Artery Dysplasia ...
Complications of DVT include postphlebitic syndrome or death from PE. Therefore, prophylaxis with anticoagulant medications, as ... Role of statins in the prevention of post-thrombotic syndrome after a deep vein thrombosis event: a systematic review and meta- ... suggested that statins may reduce postthrombotic syndrome after DVT; however, meta-analysis of the RCTs did not confirm any ...
Post-thrombotic (postphlebitic) syndrome * Nevrome de morton. * Anévrisme de laorte abdominale. * Adénofibrome ...
Postphlebitic (postthrombotic) syndrome is symptomatic chronic... read more , and postphlebitic syndrome. Treatment of lower ... Postphlebitic syndrome Chronic Venous Insufficiency and Postphlebitic Syndrome Chronic venous insufficiency is impaired venous ... Venous insufficiency and postphlebitic syndrome Chronic Venous Insufficiency and Postphlebitic Syndrome Chronic venous ... thoracic outlet syndrome Thoracic Outlet Compression Syndromes (TOS) Thoracic outlet compression syndromes are a group of ...
... professional/cardiovascular-disorders/peripheral-venous-disorders/chronic-venous-insufficiency-and-postphlebitic-syndrome. ... Chronic venous insufficiency and postphlebitic syndrome. Merck Manual Professional Version website. Available at: https://www. ...
... postphlebitic syndrome, protein C deficiency, protein S deficiency, prothrombin gene mutation, sickle cell disease, sticky ... Antiphospholipid syndrome, Behcets disease, elevated interleukin 8, Klippel Trenaunay syndrome, polyarteritis nodosa, ... postphlebitic syndrome, presence of a central venous catheter, stent, stroke, subclavian vein thrombosis, superficial ... Antiphospholipid antibody syndrome + + +/- + + + N/A ↑ *Increased impedance of flow in uterine arteries at 12-20 weeks of ...
2) and postphlebitic syndrome are the most common causes of acquired, regional lymphatic insufficiency. ...
Postphlebitic syndrome is chronic venous insufficiency that results from a blood clot in the veins... read more ... Postphlebitic syndrome is chronic venous insufficiency that results from a blood clot in the veins... read more ... or venous insufficiency Chronic Venous Insufficiency and Postphlebitic Syndrome Chronic venous insufficiency is damage to leg ... or venous insufficiency Chronic Venous Insufficiency and Postphlebitic Syndrome Chronic venous insufficiency is damage to leg ...
... also called postphlebitic syndrome) is a complication of a blood clot that forms in a deep vein. Post-thrombotic syndrome ... occurs because of damage to the vein caused by the blood clot (thrombosis).Post-thrombotic syndrome can be a long-term problem ... Top of the pagePost-thrombotic syndromePost-thrombotic syndrome ( ... Post-thrombotic syndrome. Post-thrombotic syndrome (also called ... postphlebitic syndrome) is a complication of a blood clot that forms in a deep vein. Post-thrombotic syndrome occurs because of ...
Some people may have long-term pain and swelling in the leg called postphlebitic syndrome. ...
Many hospitalized patients develop VTE, which can be fatal, can result in long-term disability from postphlebitic syndrome or ...
... severe post-phlebitic syndromes). Because of this triple risk it is important to be able to judge when to opt for surgery. ... severe post-phlebitic syndromes). Because of this triple risk it is important to be able to judge when to opt for surgery. ... Threat of "blue phlebitis" (acute arterial ischemia); threat of severe post-phlebitis syndrome (the thrombosed iliac veins do ... Threat of "blue phlebitis" (acute arterial ischemia); threat of severe post-phlebitis syndrome (the thrombosed iliac veins do ...
Post-Phlebitic Syndrome (post-thrombotic syndrome). Damage caused by DVT can reduce the flow of blood to the affected area, ... known as Post-Phlebitic Syndrome or Post-Thrombotic Syndrome, which can lead to persistent swelling of the legs, development of ...
Role of radioisotopic lymphoscintigraphy in postphlebitic syndrome of the legs. Role of radioisotopic lymphoscintigraphy in ... postphlebitic syndrome of the legs. Russo F, et al. Chir Ital. 2001 May-Jun. AuthorsRusso F1, Coscarella G, Giuliano G, De Lisa ...
... post-phlebitic syndrome, phlebitis, reversible lymphedema, and post varicose vein surgery, vein stripping, sclerotherapy, and ...
Postphlebitic syndrome, also known as post-thrombotic syndrome, is a condition that occurs after a deep vein thrombosis (DVT) ... This syndrome can appear soon after phlebitis or years later. Postphlebitic syndrome is the result of damaged or incompetent ... Postphlebitic syndrome can be difficult to diagnose, as the symptoms can be similar to other conditions such as chronic venous ... Symptoms of postphlebitic syndrome may include:. 1. Chronic pain or tenderness in the affected limb. 2. Swelling, redness, and ...
MSH )] (UMLS (ICD9CM) C0042485) =Disease or Syndrome =blood vessel disorder; =Postphlebitic syndrome ... CSP )] (UMLS (ICD9CM) C0220704) =Congenital Abnormality; Disease or Syndrome =Chromosomal anomalies; syndrome 90. VENTRI SHUNT- ... UMLS (NCI) C0948672) =Disease or Syndrome 20. Vegan Diet [Men who eat a vegan diet have lower levels of IGF-I, a protein ... UMLS (ICD9CM) C0155891) =Disease or Syndrome 28. Vehem (UMLS (NCI) C0733481) =Carbohydrate; Pharmacologic Substance ; 78. ...
Postphlebitic syndrome -. Damage to your veins from the blood clot reduces blood flow in the affected areas, causing leg pain ... Stockings can also protect the individual from post thrombotic syndrome. Someone with DVT will have to wear stockings at all ...
Post phlebitic syndrome. *Pronounced leg swelling after cast removal. *Futuro guarantee: If you received a defective product, ...
Venous stenting for post phlebitic syndrome. *For Deep Vein Thrombosis. *Catheter directed thrombolysis for iliofemoral DVT ... For Thoracic outlet syndrome or upper limb ischemia. *Carotid - Subclavian bypass Cervical rib resection with subclavian artery ...
Postphlebitic Syndrome C14.907.681.760 C14.907.617.718.760. Potassium Acetate D1.745.312. Precipitin Tests E5.478.594.760.645. ... Shy-Drager Syndrome C14.907.514.482.853 C14.907.514.741. Sick Sinus Syndrome C14.280.67.829 C14.280.67.93.249. C14.280.67.558. ... Sturge-Weber Syndrome C4.700.852. C16.320.700.852. Subclavian Steal Syndrome C14.907.253.92.956.700. Substantia Innominata ... Williams Syndrome C14.280.484.150.60.960 C14.280.484.150.535.960. Wolff-Parkinson-White Syndrome C16.131.240.400.980. Wolffian ...
Postphlebitic Syndrome C14.907.681.760 C14.907.617.718.760. Potassium Acetate D1.745.312. Precipitin Tests E5.478.594.760.645. ... Shy-Drager Syndrome C14.907.514.482.853 C14.907.514.741. Sick Sinus Syndrome C14.280.67.829 C14.280.67.93.249. C14.280.67.558. ... Sturge-Weber Syndrome C4.700.852. C16.320.700.852. Subclavian Steal Syndrome C14.907.253.92.956.700. Substantia Innominata ... Williams Syndrome C14.280.484.150.60.960 C14.280.484.150.535.960. Wolff-Parkinson-White Syndrome C16.131.240.400.980. Wolffian ...

No FAQ available that match "postphlebitic syndrome"